Yimusake Tablet: safe and efficacious for premature ejaculation.
- Author:
Lian-ming ZHAO
1
;
Hui JIANG
;
Kai HONG
;
Fu-biao LI
;
Ji-xiu XU
;
Xiang-sheng ZHANG
;
Xiang-ming MAO
;
Shao-hu ZHOU
;
Bin CHEN
;
Chen MING
;
Xiao-yong PU
;
Cheng-bin ZHU
;
Guo-sheng YANG
;
Liang-hong MA
;
Sheng-li MA
;
Xiang-an TU
;
Chun-hua DENG
;
Xiang-zhou SUN
;
You-sheng YAO
;
Bin ZHANG
;
Yi LU
;
Jin-ming JIA
;
Wei-guo MA
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Drugs, Chinese Herbal; therapeutic use; Ejaculation; drug effects; physiology; Erectile Dysfunction; drug therapy; Humans; Male; Middle Aged; Patient Satisfaction; Penile Erection; Phytotherapy; Premature Ejaculation; drug therapy; Surveys and Questionnaires; Tablets; Time Factors
- From: National Journal of Andrology 2014;20(11):1029-1034
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo objectively evaluate the efficacy and safety of Yimusake Tablet in the treatment of premature ejaculation (PE) through a multi-centered large-sample trial.
METHODSWe conducted a multi-centered, open, fixed-dose, and self-compared clinical trial among 300 patients with diagnosed PE. The trial lasted 12 weeks, including 4 weeks without any medication and 8 weeks of treatment with Yimusake Tablet, 2 pills (1 g) per night. We observed the intravaginal ejaculation latency time (IELT) before and after treatment, evaluated the safety of medication, and performed a questionnaire investigation on the patients' satisfaction.
RESULTSOf the 300 PE patients, 288 accomplished the clinical trial. The patients ranged in age from 22 to 60 years, averaging at 31.6 years. The mean IELT of the patient was 62.5 seconds at baseline, 168.9 seconds after 4 weeks of treatment with Yimusake Tablet, and 222.2 seconds after 8 weeks of medication. Among the 157 patients with normal erectile function (IIEF >21), the mean IELT was 71.4 seconds before treatment, 147.4 seconds after 4 weeks of medication, and 172.5 seconds after 8 weeks of medication. The patients' satisfaction was significantly increased after treatment. Those complicated by mild to moderate erectile dysfunction achieved different degrees of improvement in the IIEF-5 score, with a mean increase of 3.8. Only a few patients experienced mild adverse events, including constipation, dry mouth, nose bleeding, abdominal pain, and lumbosacral pain, which were all relieved without drug withdrawal.
CONCLUSIONYimusake Tablet is a safe and effective medicine for the treatment of PE.